GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oculis Holding AG (FRA:CR5) » Definitions » Selling and Marketing Expense

Oculis Holding AG (FRA:CR5) Selling and Marketing Expense : €0.00 Mil (TTM As of Sep. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Oculis Holding AG Selling and Marketing Expense?

Selling and Marketing Expense is the aggregate total amount of expenses directly related to the marketing or selling of products or services. Oculis Holding AG's Selling and Marketing Expense for the three months ended in Sep. 2024 was €0.00 Mil. Its Selling and Marketing Expense for the trailing twelve months (TTM) ended in Sep. 2024 was €0.00 Mil.


Oculis Holding AG Selling and Marketing Expense Historical Data

The historical data trend for Oculis Holding AG's Selling and Marketing Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oculis Holding AG Selling and Marketing Expense Chart

Oculis Holding AG Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Selling and Marketing Expense
- - - -

Oculis Holding AG Quarterly Data
Dec20 Jun21 Sep21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Selling and Marketing Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Oculis Holding AG Selling and Marketing Expense Calculation

Selling and Marketing Expense is the aggregate total amount of expenses directly related to the marketing or selling of products or services.

Selling and Marketing Expense for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Oculis Holding AG Selling and Marketing Expense Related Terms

Thank you for viewing the detailed overview of Oculis Holding AG's Selling and Marketing Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Oculis Holding AG Business Description

Industry
Traded in Other Exchanges
Address
Bahnhofstrasse 7, Zug, CHE, 6300
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.

Oculis Holding AG Headlines

No Headlines